Theravent, Inc. exceeds 4.5 million nights of sleep apnea and snoring treatment

SAN JOSE, Calif., Oct. 29, 2013 /PRNewswire/ -- Theravent, Inc., a medical device company providing noninvasive solutions for people with sleep disordered breathing, recently hit a milestone when their Provent® Sleep Apnea Therapy and Theravent™ Advanced Nightly Snore Therapy products exceeded 4.5 million nights of treatment, collectively. Both products feature Expiratory Positive Airway Pressure (EPAP) therapy to treat Obstructive Sleep Apnea (OSA) and snoring.

Clinically proven by leading sleep specialists to treat both snoring and OSA, EPAP therapy represents a breakthrough in the battle against sleep related breathing disorders. It features MicroValve technology, which attaches and covers the nostrils to create pressure during exhalation. EPAP keeps a person's airway open while they sleep and prevents sleep disordered breathing and snoring.

Since 2009, over four million nights of Provent have been prescribed to treat OSA patients, while more than 400,000 nights of Theravent have been used over the past year to stop snoring and achieve a quieter night's sleep.

"We're pleased to see these therapies helping people around the world by treating conditions that have been linked to serious health problems, such as high blood pressure, stroke and heart attack," said Theravent, Inc. CEO Matt Williams. "In addition, these treatments provide quieter nights for bed partners, who are often negatively affected by loss of sleep due to the sound of snoring."

Approximately 90 million Americans are suffering from either OSA or snoring. Provent, which is available only by prescription, has been validated in seven peer-reviewed clinical publications by renowned sleep experts providing consistent results in the treatment of all severities of OSA. This treatment is a simple, portable and less invasive alternative to CPAP machines for people with OSA.  Theravent, an over-the-counter product developed using similar technology as Provent, was rigorously tested in three clinical trials. The results, published in Sleep Diagnosis and Therapy, showed that it was effective in reducing and eliminating snoring.

"OSA and snoring are both global health issues in need of more effective treatment options," said Williams. "Provent and Theravent are easy to use, convenient and cost-effective for sufferers of such conditions, and are clinically proven to work."

Thousands of sleep physicians have recommended these therapies to treat patients with snoring or OSA. To learn more, visit www.theravent.com and www.proventtherapy.com, or call 1-888-SLP-WELL (1-888-757-9355).

About Theravent, Inc.
Theravent, Inc. is a privately-held medical device company dedicated to providing noninvasive medical solutions for people with sleep disordered breathing. Based on its innovative MicroValve technology and patented designs, Theravent, Inc. has developed a unique line of clinically-proven medical devices to address the continuum of sleep disorders from severe obstructive sleep apnea (OSA) to mild snoring. Theravent, Inc.'s devices work by creating expiratory positive airway pressure (EPAP). The company markets prescription-only Provent Sleep Apnea Therapy, a discreet, easy-to-use nasal device for the treatment of OSA, and Theravent Snore Therapy, an over-the-counter device for the treatment of primary snoring, in the US. Provent is also available in Australia, New Zealand, Canada, Hong Kong, Singapore and South Africa. For more information, please visit www.proventtherapy.com or www.theravent.com.

SOURCE Theravent, Inc.